Literature DB >> 27893358

The price of enhanced half-life factor IX.

Andrea Messori1, Sabrina Trippoli1.   

Abstract

Mesh:

Substances:

Year:  2016        PMID: 27893358      PMCID: PMC5490735          DOI: 10.2450/2016.0198-16

Source DB:  PubMed          Journal:  Blood Transfus        ISSN: 1723-2007            Impact factor:   3.443


× No keyword cloud information.
  4 in total

1.  The design and analysis of half-life and recovery studies for factor VIII and factor IX. Factor VIII/Factor IX Scientific and Standardization Committee of the International Society for Thrombosis and Haemostasis.

Authors:  M Morfini; M Lee; A Messori
Journal:  Thromb Haemost       Date:  1991-09-02       Impact factor: 5.249

Review 2.  Half-life extension technologies for haemostatic agents.

Authors:  Pier Mannuccio Mannucci
Journal:  Thromb Haemost       Date:  2014-10-02       Impact factor: 5.249

Review 3.  Pharmacokinetics of coagulation factors: clinical relevance for patients with haemophilia.

Authors:  S Björkman; E Berntorp
Journal:  Clin Pharmacokinet       Date:  2001       Impact factor: 6.447

Review 4.  The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.

Authors:  P Collins; E Chalmers; P Chowdary; D Keeling; M Mathias; J O'Donnell; K J Pasi; S Rangarajan; A Thomas
Journal:  Haemophilia       Date:  2016-06-16       Impact factor: 4.287

  4 in total
  1 in total

Review 1.  Factors affecting the quality, safety and marketing approval of clotting factor concentrates for haemophilia.

Authors:  Albert Farrugia; Giancarlo M Liumbruno; Fabio Candura; Samantha Profili; Josephine Cassar
Journal:  Blood Transfus       Date:  2018-09-03       Impact factor: 3.443

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.